News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Lubner David Charles
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/16/2023 |
4
| Lubner David Charles (Director) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Granted 11,459 options to buy
@ $37.94, valued at
$434.8k
|
|
| 06/05/2023 |
4
| Lubner David Charles (Director) has filed a Form 4 on POINT Biopharma Global Inc.|
Txns:
| Granted 44,749 options to buy
@ $9.12, valued at
$408.1k
|
|
| 06/02/2023 |
4
| Lubner David Charles (Director) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Granted 30,000 options to buy
@ $4.79, valued at
$143.7k
|
|
| 05/25/2023 |
4
| Lubner David Charles (Director) has filed a Form 4 on Dyne Therapeutics, Inc.|
Txns:
| Granted 24,900 options to buy
@ $13.49, valued at
$335.9k
|
|
| 11/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2022 |
4
| Lubner David Charles (Director) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Granted 16,911 options to buy
@ $4.26, valued at
$72k
|
|
| 06/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/07/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/06/2021 |
4
| Lubner David Charles (Director) has filed a Form 4 on Gemini Therapeutics, Inc. /DE|
Txns:
| Granted 17,245 options to buy
@ $3.8, valued at
$65.5k
|
|
| 07/08/2021 |
4
| Lubner David Charles (Director) has filed a Form 4 on POINT Biopharma Global Inc.|
Txns:
| Granted 25,000 options to buy
@ $8.47, valued at
$211.8k
|
|
| 05/27/2021 |
4
| Lubner David Charles (Director) has filed a Form 4 on Dyne Therapeutics, Inc.|
Txns:
| Granted 19,596 options to buy
@ $19.56, valued at
$383.3k
|
|
| 04/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/15/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/09/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/23/2020 |
4
| Lubner David Charles (Director) has filed a Form 4 on Dyne Therapeutics, Inc.|
Txns:
| Converted 53,625 shares
@ $0
Granted 11,156 options to buy
@ $5.54, valued at
$61.8k
Granted 14,444 options to buy
@ $5.54, valued at
$80k
Bought 177,872 preferred shares
@ $2.811, valued at
$500k
Converted 177,872 preferred shares
@ $0 |
|
| 04/03/2020 |
4
| Lubner David Charles (Executive VP and CFO) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 15,622 shares
@ $48, valued at
$749.9k
Disposed/sold 115,572 options to buy
@ $2.87, valued at
$331.7k
Disposed/sold 92,283 options to buy
@ $2.87, valued at
$264.9k
Disposed/sold 28,571 options to buy
@ $5.6, valued at
$160k
Disposed/sold 112,500 options to buy
@ $16.64, valued at
$1.9M
Disposed/sold 62,500 options to buy
@ $7.33, valued at
$458.1k
Disposed/sold 133,000 options to buy
@ $21, valued at
$2.8M
Disposed/sold 10,416 restricted stock units
@ $0 |
|
| 06/07/2019 |
4
| Lubner David Charles (Director) has filed a Form 4 on Nightstar Therapeutics plc|
Txns:
| Disposed/sold 29,124 shares
@ $25.5, valued at
$742.7k
Disposed/sold 18,200 options to buy
@ $12.27, valued at
$223.3k
Disposed/sold 21,000 options to buy
@ $13.57, valued at
$285k
|
|
| 02/05/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/29/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/05/2018 |
4
| Lubner David Charles (Executive V.P. & CFO) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Granted 62,500 options to buy
@ $7.33, valued at
$458.1k
Granted 31,250 restricted stock units
@ $0 |
|
| 02/03/2017 |
4
| Lubner David Charles (Executive V.P. & CFO) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Granted 112,500 options to buy
@ $16.64, valued at
$1.9M
|
|
| 10/31/2016 |
4
| Lubner David Charles (EVP & CFO) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Granted 29,285 options to buy
@ $2.87, valued at
$84k
|
|
| 08/17/2015 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 07/15/2015 |
4
| Lubner David Charles (SVP and CFO) has filed a Form 4 on TETRAPHASE PHARMACEUTICALS INC|
Txns:
| Sold 7,500 shares
@ $48.92, valued at
$366.9k
Exercised 5,799 options to buy
@ $2.03, valued at
$11.8k
Exercised 1,701 options to buy
@ $7.94, valued at
$13.5k
|
|
| 06/16/2015 |
4
| Lubner David Charles (SVP and CFO) has filed a Form 4 on TETRAPHASE PHARMACEUTICALS INC|
Txns:
| Sold 10,000 shares
@ $41.29, valued at
$412.9k
Sold 7,500 shares
@ $41.67, valued at
$312.5k
Exercised 7,500 options to buy
@ $2.03, valued at
$15.2k
|
|
| 05/18/2015 |
4
| Lubner David Charles (SVP and CFO) has filed a Form 4 on TETRAPHASE PHARMACEUTICALS INC|
Txns:
| Sold 7,684 shares
@ $39.28, valued at
$301.8k
Sold 7,316 shares
@ $39.28, valued at
$287.4k
Exercised 7,684 options to buy
@ $2.03, valued at
$15.6k
Exercised 7,316 options to buy
@ $2.03, valued at
$14.9k
|
|
| 01/09/2015 |
4
| Lubner David Charles (SVP and CFO) has filed a Form 4 on TETRAPHASE PHARMACEUTICALS INC|
Txns:
| Granted 100,000 options to buy
@ $39.94, valued at
$4M
|
|
| 06/18/2014 |
4
| Lubner David Charles (SVP and CFO) has filed a Form 4 on TETRAPHASE PHARMACEUTICALS INC|
Txns:
| Sold 13,530 shares
@ $12.51, valued at
$169.3k
|
|
| 03/10/2014 |
4
| Lubner David Charles (SVP and CFO) has filed a Form 4 on TETRAPHASE PHARMACEUTICALS INC|
Txns:
| Sold 4,510 shares
@ $13.65, valued at
$61.6k
|
|
| 02/13/2014 |
4
| Lubner David Charles (SVP and CFO) has filed a Form 4 on TETRAPHASE PHARMACEUTICALS INC|
Txns:
| Sold 4,506 shares
@ $13.92, valued at
$62.7k
|
|
| 02/11/2014 |
4
| Lubner David Charles (SVP and CFO) has filed a Form 4 on TETRAPHASE PHARMACEUTICALS INC|
Txns:
| Sold 9,928 shares
@ $14.22, valued at
$141.2k
Exercised 34,482 options to buy
@ $0.87, valued at
$30k
Exercised 33,295 options to buy
@ $2.03, valued at
$67.6k
Exercised 20,614 options to buy
@ $2.03, valued at
$41.8k
|
|
|
|
|